Search

Peter J Ansell

from Grayslake, IL
Age ~49
Get Report
Also known as:
Peter S Ansell, Pete J Ansell, Peter J Ansel
Phone and address:
287 S Seymour Ave, Volo, IL 60030
(847) 548-8483
Related to:
Alyson P Ansell, 31Gabi AnsellElizabeth Ansell
Connected to:
Allen G Ansell, 42Barbara A Ansell, 52Danny R Ansell, 46Gina M Ansell, 60Jeanne Ansell, 65Jennifer L Ansell, 42Laurie Ansell, 63Mark R Ansell, 82Melissa M Ansell, 43Olivia B Ansell, 34

Peter Ansell Phones & Addresses

  • 287 S Seymour Ave, Grayslake, IL 60030 (847) 548-8483
  • Cedarburg, WI
  • 859 Winthrop Ave, Revere, MA 02151 (781) 853-1333
  • 5362 Rocky Fork Dr, Columbia, MO 65202 (573) 817-3333
  • 4001 Hyde Park Ave, Columbia, MO 65201 (573) 817-3333
  • 104 Diego Ct, Columbia, MO 65203 (573) 817-3333
  • 2061 4Th St, Springfield, IL 62703 (217) 544-7986
  • Lane, IL
  • Saint Louis, MO
  • Buffalo Grove, IL

Publications

Us Patents

Pigf-1 Assay And Kits And Components Thereof

View page
US Patent:
20100004306, Jan 7, 2010
Filed:
Jun 17, 2009
Appl. No.:
12/486671
Inventors:
Evelyn Mary McKeegan - Lake Forest IL, US
Saul A. Datwyler - Evanston IL, US
David J. Hawksworth - Lake Villa IL, US
Don M. Laird - Mundelein IL, US
Dominick L. Pucci - Libertyville IL, US
David C. Sogin - Highland Park IL, US
Joan D. Tyner - Beach Park IL, US
Robert N. Ziemann - Lindenhurst IL, US
Peter James Ansell - Grayslake IL, US
Ke K. Zhang - Glenview IL, US
Assignee:
ABBOTT LABORATORIES - Abbott Park IL
International Classification:
A61K 31/416
G01N 33/566
A61P 35/00
US Classification:
514406, 436501
Abstract:
The present disclosure relates to, among other things, methods for determining whether a subject receiving treatment with a drug has obtained an efficacious blood level of the drug. Moreover, the present disclosure also relates to methods of determining whether a subject predisposed to or suffering from a disease will benefit from treatment with a drug, and the response of a subject receiving treatment (e.g., such as for cancer) by monitoring biomarkers of angiogenesis. In particular, the disclosure relates to PlGF-1 companion diagnostic methods and products.

Methods For Predicting Sensitivity To Treatment With A Targeted Tyrosine Kinase Inhibitor

View page
US Patent:
20120115745, May 10, 2012
Filed:
Nov 9, 2011
Appl. No.:
13/292959
Inventors:
Evelyn M. McKeegan - Lake Forest IL, US
Peter Ansell - Grayslake IL, US
Barry L. Dowell - Mundelein IL, US
Ke Zhang - Grand Forks ND, US
Viswanath Devanarayan - Souderton PA, US
International Classification:
C40B 30/04
C40B 40/10
G01N 33/566
US Classification:
506 9, 435 71, 436501, 435 74, 506 18
Abstract:
The present disclosure relates generally to the evaluation and/or treatment of a subject having or suspected of having a neoplastic condition, and in particular to the use of biomarkers for identifying patients receptive to a certain drug therapy, and which permit monitoring of patient response to such therapy.

Methods For Predicting Sensitivity To Treatment With A Targeted Tyrosine Kinase Inhibitor

View page
US Patent:
20120190563, Jul 26, 2012
Filed:
May 4, 2011
Appl. No.:
13/100869
Inventors:
Evelyn M. McKeegan - Lake Forest IL, US
Peter Ansell - Grayslake IL, US
Barry L. Dowell - Mundelein IL, US
Ke Zhang - Grand Forks ND, US
Viswanath Devanarayan - Souderton PA, US
Assignee:
ABBOTT LABORATORIES - Abbott Park IL
International Classification:
C40B 30/04
G01N 33/567
C40B 40/10
G01N 33/566
US Classification:
506 9, 436501, 435 723, 506 18
Abstract:
Methods and kits for predicting the sensitivity of a cancer to treatment with a targeted tyrosine kinase inhibitor are disclosed.

Marker To Predict And Monitor Response To Aurora Kinase B Inhibitor Therapy

View page
US Patent:
20160153052, Jun 2, 2016
Filed:
Dec 2, 2015
Appl. No.:
14/957059
Inventors:
- North Chicago IL, US
Peter Ansell - Grayslake IL, US
Paul Hessler - Hainesville IL, US
Lloyd Lam - Libertyville IL, US
Chris Tse - Libertyville IL, US
Assignee:
AbbVie Inc. - North Chicago IL
International Classification:
C12Q 1/68
Abstract:
The present invention relates to diagnostic assays useful in classification of patients for selection of cancer therapy with one or more Aurora kinase B inhibitors. In particular, the present invention relates to identifying the genetic defects in the CDKN2A locus which exhibit a heightened dependency on Aurora kinase activity, identifying patients eligible to receive Aurora kinase inhibitor therapy, either as monotherapy or as part of combination therapy, and monitoring patient response to such therapy.
Control profile
Peter J Ansell from Grayslake, IL, age ~49 Get Report